News

Tom Ryder Joins Focused Ultrasound Foundation Board of Directors

CHARLOTTESVILLE, VA – Thomas O. Ryder, an investor, entrepreneur, and retired corporate executive, was elected to the Focused Ultrasound Foundation’s Board of Directors at their March 1 meeting.

Ryder has served as Chairman and CEO of the Reader’s Digest Association and President of American Express’s Travel Related Services International, Merchant Services Worldwide, and American Express Publishing Worldwide divisions.

He has experience in the publishing industry, having worked at Time Inc., CBS, and Education Today Company, Inc. where he was co-founder and CEO.

Ryder has also served on numerous boards, including at Amazon for 20 years, during which time he was audit committee chairman and the first lead independent director.

Other previous board appointments have included Starwood Hotels, RPX Corporation, Startek Corp, American Express International Bank, and Virgin Mobile – where he was Chairman.

He is also a prolific writer on the subjects of food and wine.

“Tom brings his unsurpassed skills and experience to the Foundation’s leadership team,” said Foundation Chairman Neal F. Kassell, MD. “He will help to facilitate our efforts to overcome barriers and take advantage of opportunities to shorten the time for focused ultrasound to become a global standard of care.”

Ryder is also an essential tremor patient who underwent focused ultrasound therapy for the disorder in 2021.

“Focused ultrasound fixed a major problem I had with essential tremor and changed my life,” he explains. “I truly hope my tenure on the Foundation Board of Directors will give me the opportunity to share that miracle with others in similar need.”

Read more here.

Recent News

11/21/2025

A new era of global growth: George Mason and Naugen launch international innovation accelerator

This month, a new Northern Virginia International Soft-Landing Accelerator (NISA) program, designed to help start-ups from around the globe find guidance, connections, and lab or office spaces at no cost, was launched to help develop new technologies in life sciences.Applications are now open for the first NISA cohort. Participants in the six-month program will have

11/20/2025

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia’s life sciences ecosystem, higher-ed universities, and community colleges on October 31. This

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical